Premium
Review article: management of chronic hepatitis C in patients with contraindications to anti‐viral therapy
Author(s) -
Carreño V.
Publication year - 2014
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.12562
Subject(s) - medicine , ribavirin , ursodeoxycholic acid , glycyrrhizin , amantadine , hepatitis c , chronic hepatitis , interferon , silibinin , intensive care medicine , immunology , virus , pharmacology
Summary Background There are patients with chronic hepatitis C who are not eligible for the current interferon‐based therapies or refuse to be treated due to secondary effects. Aim To provide information on alternative treatments for the management of these patients. Methods A PubMed search was performed to identify relevant literature. Search terms included hepatitis C virus, anti‐inflammatory treatment, antioxidant, natural products and alternative treatment, alone or in combination. Additional publications were identified using the references cited by primary and review articles. Results Several approaches, such as iron depletion (phlebotomy), treatment with ursodeoxycholic acid or glycyrrhizin, have anti‐inflammatory and/or anti‐fibrotic effects. Life interventions like weight loss, exercise and coffee consumption are associated with a biochemical improvement. Other alternatives (ribavirin monotherapy, amantadine, silibinin, vitamin supplementation, etc.) do not have any beneficial effect or need to be tested in larger clinical studies. Conclusion There are therapeutic strategies and lifestyle interventions that can be used to improve liver damage in patients with chronic hepatitis C who cannot receive or refuse interferon‐based treatments.